Vaginal dryness affecting sexual comfort is one of the most common reasons women reduce or stop sexual activity — and one of the least likely to be discussed with a healthcare provider. The burning, tearing, or rawness of intercourse without adequate lubrication is not something to simply manage with commercial lubricants indefinitely. It is a symptom of tissue-level changes from hormonal deficiency that has highly effective treatment.
The distinction between lubricants and treatment matters enormously. Lubricants reduce friction during intercourse by providing temporary moisture — they do not address the underlying tissue thinning, reduced elasticity, and vascular changes that cause the dryness. Treatment with local estrogen or non-estrogen alternatives restores the tissue itself — producing lasting improvement in natural lubrication, tissue resilience, and sexual comfort that lubricants alone cannot achieve.
- Pain or burning with penetration from friction against dry, thinned vaginal tissue
- A tearing or raw sensation during or after intercourse that may persist for hours or days
- Reduced natural lubrication response to arousal — the vasocongestion-driven lubrication that normally accompanies sexual arousal is diminished when estrogen is low
- Post-coital spotting or light bleeding from fragile vaginal tissue
- Vaginal tightness or narrowing from tissue atrophy that makes penetration increasingly difficult over time without treatment
- Avoidance of intercourse or intimacy because of anticipated or experienced pain
- Reduction in sexual desire secondary to pain anticipation — a rational protective response that is often misidentified as a primary desire problem
- Relationship strain from reduced sexual activity or from managing pain during intimacy
Menopause and Perimenopause
The most sustained cause of vaginal dryness affecting sexual function. Declining and then absent ovarian estrogen produces progressive tissue thinning, reduced lubrication capacity, and reduced elasticity that worsen over time without treatment. This is genitourinary syndrome of menopause — and it does not improve spontaneously. Full GSM detail →
Breastfeeding
Elevated prolactin during breastfeeding suppresses ovarian estrogen, producing a temporary hypoestrogenic state with identical vaginal effects to menopause. Many breastfeeding women experience significant dyspareunia from vaginal dryness that is not recognized as a reversible, treatable condition. Low-dose local vaginal estrogen is compatible with breastfeeding and specifically addresses this.
Hormonal Contraception
Certain combined oral contraceptives and progestin-only methods reduce free estrogen and androgen levels in ways that produce vaginal dryness and reduced arousal lubrication. Women who develop pain with intercourse after starting hormonal contraception should discuss the specific formulation — switching to a different formulation is often the most effective solution.
Cancer Treatment
Chemotherapy, pelvic radiation, and hormonal cancer treatments — particularly aromatase inhibitors — produce vaginal dryness that is often more severe than natural menopause. Management options are available and should be part of the oncologic and gynecologic care plan for women experiencing this. The specific options depend on the cancer type and treatment in use and require individualized clinical discussion.
Lubricants and Moisturizers
Water-based or silicone-based lubricants used during intercourse reduce friction and immediate discomfort. Vaginal moisturizers used regularly (2-3 times per week) maintain vaginal moisture and reduce pH elevation between sexual encounters. These are appropriate first measures and useful ongoing adjuncts, but do not reverse tissue atrophy.
Local Vaginal Estrogen
Low-dose vaginal estrogen — cream, ring, tablet, or suppository — restores vaginal epithelial thickness, elasticity, and natural lubrication capacity with minimal systemic absorption. It is the most effective tissue-restorative treatment available and produces lasting improvement that lubricants cannot replicate. Most women notice meaningful improvement within 4 to 12 weeks of consistent use.
Non-Estrogen Prescription Options
Ospemifene (Osphena) is an oral non-estrogen option that provides tissue-selective estrogen-like effects on vaginal tissue, approved for dyspareunia from GSM. Prasterone (Intrarosa), a vaginal DHEA suppository, is another local non-estrogen option. Both provide meaningful tissue improvement for women who prefer to avoid estrogen.
Many women have been managing painful intercourse from vaginal dryness with lubricants for years without knowing that treatments exist which restore the tissue itself and make comfortable intimacy possible without ongoing workarounds. Treatment is highly effective, widely available, and accessible to most women regardless of their ability to use systemic hormones.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here to provide that treatment — at both our Lapeer and Rochester Hills offices, without a referral required.
Our team at Lapeer Women’s Health offers effective local and systemic options at both our Lapeer and Rochester Hills offices. No referral required.
Schedule a Gynecologic VisitEducational purposes only. Not medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.